|Dr. Reza Zadno||Pres & CEO||676.7k||N/A||1955|
|Dr. Rajesh K. Rajpal||Chief Medical Officer & Member of Advisory Board||393.15k||N/A||1963|
|Mr. James Schuermann||Chief Bus. Officer||321.78k||N/A||1968|
|Mr. Joseph E. Gilliam||CFO, Sr. VP of Corp. Devel. & Director||N/A||N/A||1976|
|Mr. Sujal N. Bhalakia||VP of Operations||N/A||N/A||N/A|
Avedro, Inc., an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations. Its Avedro Corneal Remodeling platform treats corneal ectatic disorders and corrects refractive conditions; and KXL system in combination with Photrexa drug formulations used for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro sells its products primarily to ophthalmologists, hospitals, and ambulatory surgery centers through a direct sales force in the United States, as well as through medical device distributors internationally. The company was formerly known as ThermalVision, Inc. and changed its name to Avedro, Inc. in October 2005. Avedro, Inc. was incorporated in 2002 and is headquartered in Waltham, Massachusetts. As of November 21, 2019, Avedro, Inc. operates as a subsidiary of Glaukos Corporation.
Avedro, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.